top of page
Search
  • Writer's pictureSBIJI Innovation

Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101

Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020


– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate


Read More

15 views0 comments

Recent Posts

See All

Comments


bottom of page